Suchergebnisse - "Minassian, Angela M"

PubPharm (40)

1

A systematic analysis of the human immune response to Plasmodium vivax

enthalten in: The Journal of clinical investigation | 2023

von Bach, F. | Muñoz Sandoval, D. | Mazurczyk, M. | +13

2

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3) : A randomised controlled trial

enthalten in: The Journal of infection | 2023

von Kelly, E. | Greenland, M. | de Whalley, P. | +31

3

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK : eight-month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2023

von Liu, X. | Munro, A. | Wright, A. | +59

4

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

enthalten in: Science translational medicine | 2023

von Hou, M. | Barrett, J. | Themistocleous, Y. | +33

UpdateOf: medRxiv. 2022 May 30;:. - PMID 35664997

5

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Heath, P. | Galiza, E. | Baxter, D. | +42

6

Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

enthalten in: Frontiers in immunology | 2023

von Barrett, J. | Silk, S. | Mkindi, C. | +18

7

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST) : a multicentre, blinded, phase 2, randomised trial

enthalten in: The Lancet. Infectious diseases | 2022

von Munro, A. | Feng, S. | Janani, L. | +153

CommentIn: Lancet Infect Dis. 2022 Aug;22(8):1092-1093. - PMID 35550263

8

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK : Three month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2022

von Liu, X. | Munro, A. | Feng, S. | +56

CommentIn: J Infect. 2023 Feb;86(2):154-225. - PMID 36509358

9

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines : an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Respiratory medicine | 2022

von Toback, S. | Galiza, E. | Cosgrove, C. | +117

10

The challenges of Plasmodium vivax human malaria infection models for vaccine development

enthalten in: Frontiers in immunology | 2022

von Roobsoong, W. | Yadava, A. | Draper, S. | +2